About this data
Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.
no dose adjustment
- Company
- Rehman Medical Institute - RMI
- Mechanism
- Mechanism not yet reported
- Route
- Route not yet reported
- Recruiting trials
- 3 recruiting
Efficacy results: Not yet reported
3 recruiting studies currently listed on ClinicalTrials.gov.
Data source: ClinicalTrials.gov · trial data as of Nov 3, 2026
Find a Clinical Trial Near Me
See recruiting studies for no dose adjustment and check eligibility with the study team.
Trial details
-
Recruiting NCT NCT07202052
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT)
Not yet reported, Not yet reported Monash University 900 participants Est. completion 2027-03-31 3 sitesOther conditions: Myeloma, Non-Hodgkin's Lymphoma, LeukemiaView official trial listing → -
Recruiting NCT NCT07202065
Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig)
Not yet reported, Not yet reported Monash University 900 participants Est. completion 2027-03-31 3 sitesOther conditions: Myeloma, Non Hodgkin's Lymphoma, LeukemiaView official trial listing → -
Recruiting NCT NCT07604805
Efficacy and Safety of Qishen Yiqi Dropping Pills in Patients With Severe Pulmonary Hypertension
Not yet reported Guangdong Provincial People's Hospital 120 participants Est. completion 2030-12-31 1 siteOther conditions: Idiopathic Pulmonary HypertensionView official trial listing → -
Completed NCT NCT00048672
Therapy of Early Chronic Phase CML With Gleevec
Not yet reported M.D. Anderson Cancer Center 50 participants Est. completion 2013-08 1 site Stand-aloneOther conditions: Leukemia, Myeloid, Chronic-PhaseView official trial listing → -
Completed NCT NCT00478231
Multicenter, Safety Study Of Maraviroc
Not yet reported ViiV Healthcare 209 participants Est. completion 2010-09 16 sites Stand-aloneOther conditions: Acquired Immunodeficiency Syndrome, HIV InfectionView official trial listing → -
Completed NCT NCT00645840
Anti-inflammatory Therapy With Anakinra in Newly Diagnosed Type 1 Diabetes
Not yet reported, Not yet reported University of Texas Southwestern Medical Center 15 participants Est. completion 2009-09 1 site Stand-aloneOther conditions: Type 1 Diabetes MellitusView official trial listing → -
Completed NCT NCT00733616
Efficacy and Safety Study of Combination Therapy With Docetaxel-oxaliplatin-capecitabine in Patients With Advanced Gastric Adenocarcinoma and Intermediate General Status
Not yet reported Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD) 44 participants Est. completion 2012-05 1 site Stand-aloneOther conditions: Gastric CancerView official trial listing → -
Completed NCT NCT00763490
Trial Of Double Umbilical Cord Blood Transplantation
Not yet reported University of Michigan Rogel Cancer Center 20 participants Est. completion 2015-10 1 site Stand-aloneOther conditions: Hematological MalignanciesView official trial listing → -
Completed NCT NCT01310244
MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLC
Not yet reported, Not yet reported Acrotech Biopharma Inc. 23 participants Est. completion 2015-08 4 sites Stand-aloneOther conditions: Stage IV Non-small Cell Lung CancerView official trial listing → -
Completed NCT NCT01332149
Study To Evaluate Efficacy, Safety And Tolerability Of Lyrica In Patients With Painful Diabetic Peripheral Neuropathy
Not yet reported Pfizer's Upjohn has merged with Mylan to form Viatris Inc. 626 participants Est. completion 2014-06 30 sites Stand-aloneOther conditions: Diabetic Neuropathy, PainfulView official trial listing → -
Withdrawn NCT NCT02269644
A P3 Comparator Trial in Community Acquired Bacterial Pneumonia
Not yet reported Durata Therapeutics Inc., an affiliate of Allergan plc Est. completion 2016-12 1 siteOther conditions: Community Acquired PneumoniaView official trial listing → -
Terminated NCT NCT03382886
Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma
Not yet reported University of Utah 1 participants Est. completion 2019-07-02 1 site Stand-aloneOther conditions: Hepatocellular CarcinomaView official trial listing → -
Completed NCT NCT03597555
Sodium Oxybate in Idiopathic Hypersomnia
Not yet reported, Not yet reported University Hospital, Montpellier 48 participants Est. completion 2023-04-12 1 site Stand-aloneOther conditions: Idiopathic HypersomniaView official trial listing → -
Completed NCT NCT03788967
Study to Assess the Efficacy, Safety and Pharmacokinetics of Orally Administered Tebipenem Pivoxil Hydrobromide (SPR994) Compared to Intravenous Ertapenem in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
Not yet reported Spero Therapeutics 1372 participants Est. completion 2020-05-27 96 sitesOther conditions: Complicated Urinary Tract Infection, Acute PyelonephritisView official trial listing → -
Status unknown NCT NCT03840057
Metoclopramide, Azithromycin, or Nondrug Pretreatment for UGIB to Reduce Second Endoscopy
Not yet reported Waihong Chung 435 participants Est. completion 2021-07 1 site Stand-aloneOther conditions: Gastro Intestinal Bleeding, Upper Gastrointestinal BleedingView official trial listing → -
Withdrawn NCT NCT03927248
PAC-1 for Treatment of Refractory, Metastatic Kidney Cancer
Not yet reported, Not yet reported HealthPartners Institute Est. completion 2021-12 Stand-aloneOther conditions: Metastatic Renal Cell CarcinomaView official trial listing → -
Terminated NCT NCT03994783
Transplant Antibody-Mediated Rejection: Guiding Effective Treatments
Not yet reported Imperial College London 3 participants Est. completion 2023-01-09 1 site Stand-aloneOther conditions: Kidney Transplant Rejection, Antibody-mediated RejectionView official trial listing → -
Completed NCT NCT04571164
A Study to Evaluate the Effectiveness and Safety of LY03003 in Patients With Early Primary PD
Not yet reported Luye Pharma Group Ltd. 294 participants Est. completion 2022-09-27 1 site Stand-aloneOther conditions: Parkinson DiseaseView official trial listing → -
Terminated NCT NCT04575610
IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)
Not yet reported Yale University 7 participants Est. completion 2021-10-06 1 site Stand-aloneOther conditions: COVID-19View official trial listing → -
Terminated NCT NCT04876716
Azole-echinocandin Combination Therapy for Invasive Aspergillosis
Not yet reported Erasmus Medical Center 66 participants Est. completion 2024-05-01 4 sites Stand-aloneOther conditions: Invasive AspergillosisView official trial listing → -
Completed NCT NCT06412926
A Study to Learn About How Much Emodepside Gets Absorbed in the Blood and How Food Affects Its Absorption When Given as a New Type of Tablet to Healthy Participants
Not yet reported Bayer 14 participants Est. completion 2024-08-27 1 site Stand-aloneOther conditions: Soil-transmitted Helminth Infection, Onchocerciasis (River Blindness)View official trial listing → -
Active, not recruiting NCT NCT06504199
Obinutuzumab, Zanubrutinib, and Lenalidomide Followed Short-Cycle of Obinutuzumab and Cytarabine in Newly Diagnosed Mantle Cell Lymphoma
Not yet reported Institute of Hematology & Blood Diseases Hospital, China 39 participants Est. completion 2028-12-31 2 sites Stand-aloneOther conditions: Mantle Cell LymphomaView official trial listing → -
Status unknown NCT NCT06509971
A Study of QL1706 (an Anti-PD-1/CTLA-4 Combined Antibody) Combined With Albumin-bound Paclitaxel and Bevacizumab in the Treatment of Platinum-resistant Recurrent Ovarian Cancer
Not yet reported West China Second University Hospital 39 participants Est. completion 2026-06 Stand-aloneOther conditions: Platinum-resistant Recurrent Ovarian CancerView official trial listing → -
Active, not recruiting NCT NCT06584435
A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer
Not yet reported Tianjin Medical University Second Hospital 100 participants Est. completion 2027-11-01 1 site Stand-aloneOther conditions: High-risk Renal Cell CarcinomaView official trial listing → -
Not yet recruiting NCT NCT06857786
Postoperative Adjuvant Therapy for CT041 Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma Patients
Not yet reported Peking University 48 participants Est. completion 2030-06-30 3 sites Stand-aloneOther conditions: Gastroesophageal Junction Adenocarcinoma, Gastric AdenocarcinomaView official trial listing → -
Not yet recruiting NCT NCT07713992
Efficacy and Safety of Mazdutide in Patients With Type 2 Diabetes Mellitus and Moderate to Severe Nonalcoholic Fatty Liver Disease Previously Treated With Semaglutide
Not yet reported Tianjin Medical University 72 participants Est. completion 2028-02-01Type 2 diabetesMASLDView official trial listing → -
Completed NCT NCT07746479
A Study to Evaluate the Efficacy and Safety of LZM012 ( Psoriasis )
Not yet reported Livzon Pharmaceutical Group Inc. 244 participants Est. completion 2026-01-26 1 site Stand-aloneOther conditions: PsoriasisView official trial listing → -
Not yet recruiting NCT NCT07909915
Effectiveness and Tolerability of a Treat-to-Target Versus Fixed-Dose Statin Strategy in Patients With Atherosclerotic Cardiovascular Disease: A Randomized Controlled Trial
Not yet reported Rehman Medical Institute - RMI 178 participants Est. completion 2027-06 1 siteCardiovascular disease Other conditions: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia, Cardio Vascular DiseaseView official trial listing →
Efficacy history
Not yet reported.
Safety
Not yet reported.
Sources
Related On The Pen coverage
No related coverage yet.
This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.